Cell and gene therapies have become very effective for treating patients with hematologic malignancies, hemoglobinopathies, and immune deficiencies, but most patients are being treated at academic medical centers. It’s important to make these therapies available to more patients. For hospitals without specialized cell processing facilities the blood bank or hospital pharmacy is well suited to handle these products. The administration of in vivo gene therapies which does not involve the infusion of cells and is similar to the intravenous administration of drugs, can be handled by pharmacies. Providing cellular therapies is more difficult since most are cryopreserved. To provide these therapies a hospital must have access to −80 °C or liquid nitrogen freezers for storage of the cellular therapy, the ability to thaw and quickly administer the therapy, and a system to document their administration. The difficulties associated with providing these therapies at more medical centers and how to overcome these issues are discussed.
- Open Access
- Review
Expanding Access to Cell and Gene Therapies
Author Information
Received: 15 June 2026 | Revised: 20 August 2026 | Accepted: 12 October 2026 | Published: 28 October 2026
Abstract
References
- 1.
Blaese, R.M.; Culver, K.W.; Miller, A.D.; et al. T Lymphocyte-Directed Gene Therapy for ADA-SCID: Initial Trial Results after 4 Years. Science 1995, 270, 475–480. https://doi.org/10.1126/science.270.5235.475.
- 2.
Malech, H.L.; Garabedian, E.K.; Hsieh, M.M. Evolution of Gene Therapy, Historical Perspective. Hematol. Oncol. Clin. North Am. 2022, 36, 627–645. https://doi.org/10.1016/j.hoc.2022.05.001.
- 3.
Rosenberg, S.A.; Yang, J.C.; Sherry, R.M.; et al. Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy. Clin. Cancer Res. 2011, 17, 4550–4557. https://doi.org/10.1158/1078-0432.ccr-11-0116.
- 4.
Morgan, R.A.; Dudley, M.E.; Wunderlich, J.R.; et al. Cancer Regression in Patients after Transfer of Genetically Engineered Lymphocytes. Science 2006, 314, 126–129. https://doi.org/10.1126/science.1129003.
- 5.
Johnson, L.A.; Morgan, R.A.; Dudley, M.E.; et al. Gene Therapy with Human and Mouse T-Cell Receptors Mediates Cancer Regression and Targets Normal Tissues Expressing Cognate Antigen. Blood 2009, 114, 535–546. https://doi.org/10.1182/blood-2009-03-211714.
- 6.
Kochenderfer, J.N.; Wilson, W.H.; Janik, J.E.; et al. Eradication of B-Lineage Cells and Regression of Lymphoma in a Patient Treated with Autologous T Cells Genetically Engineered to Recognize CD19. Blood 2010, 116, 4099–4102. https://doi.org/10.1182/blood-2010-04-281931.
- 7.
Kalos, M.; Levine, B.L.; Porter, D.L.; et al. T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia. Sci. Transl. Med. 2011, 3, 95ra73. https://doi.org/10.1126/scitranslmed.3002842.
- 8.
Koehler, P.; Schmidt, P.; Hombach, A.A.; et al. Engineered T Cells for the Adoptive Therapy of B-Cell Chronic Lymphocytic Leukaemia. Adv Hematol. 2012, 2012, 595060. https://doi.org/10.1155/2012/595060.
- 9.
Cappell, K.M.; Kochenderfer, J.N. Long-Term Outcomes Following CAR T Cell Therapy: What We Know So Far. Nat Rev Clin Oncol. 2023, 20, 359–371. https://doi.org/10.1038/s41571-023-00754-1.
- 10.
Raguram, A.; Banskota, S.; Liu, D.R. Therapeutic in Vivo Delivery of Gene Editing Agents. Cell 2022, 185, 2806–2827. https://doi.org/10.1016/j.cell.2022.03.045.
- 11.
Bimbo, J.F.; van Diest, E.; Murphy, D.E.; et al. T Cell-Specific Non-Viral DNA Delivery and in Vivo CAR-T Generation Using Targeted Lipid Nanoparticles. J. Immunother. Cancer 2025, 13, e011759. https://doi.org/10.1136/jitc-2025-011759.
- 12.
Allen, E.S.; Conry-Cantilena, C. Mobilization and Collection of Cells in the Hematologic Compartment for Cellular Therapies: Stem Cell Collection with G-CSF/Plerixafor, Collecting Lymphocytes/Monocytes. Semin. Hematol. 2019, 56, 248–256. https://doi.org/10.1053/j.seminhematol.2019.11.003.
- 13.
Hunter, T.L.; Bao, Y.; Zhang, Y.; et al. In Vivo CAR T Cell Generation to Treat Cancer and Autoimmune Disease. Science 2025, 388, 1311–1317. https://doi.org/10.1126/science.ads8473.
- 14.
Stroncek, D.F.; Ren, J.; Lee, D.W.; et al. Myeloid Cells in Peripheral Blood Mononuclear Cell Concentrates Inhibit the Expansion of Chimeric Antigen Receptor T Cells. Cytotherapy 2016, 18, 893–901. https://doi.org/10.1016/j.jcyt.2016.04.003.
- 15.
Dreyzin, A.; Shao, L.; Cai, Y.; et al. Immunophenotype of CAR T Cells and Apheresis Products Predicts Response in CD22 CAR T Cell Trial for B Cell Acute Lymphoblastic Leukemia. Mol. Ther. 2025, 33, 3360–3374. https://doi.org/10.1016/j.ymthe.2025.03.019.
- 16.
Ahmed, N.; Sun, F.; Teigland, C.; et al. Chimeric Antigen Receptor T-Cell Access in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Association of Access with Social Determinants of Health and Travel Time to Treatment Centers. Transplant. Cell. Ther. 2024, 30, 714–725. https://doi.org/10.1016/j.jtct.2024.04.017.
- 17.
Ahmed, N.; Shahzad, M.; Shippey, E.; et al. Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access. Transplant. Cell. Ther. 2022, 28, 358–364. https://doi.org/10.1016/j.jtct.2022.04.008.
- 18.
Rioufol, C.; Wichmann, C. Receiving, Handling, Storage, Thawing, Distribution, and Administration of CAR-T Cells Shipped from the Manufacturing Facility. In The EBMT/EHA CAR-T Cell Handbook; Springer International Publishing: Cham, Switzerland, 2022; pp. 37–43. https://doi.org/10.1007/978-3-030-94353-0_7.
- 19.
Talarmin, C.; Kerob, S.; Cartier, F.; et al. Quality Risk Management of the Chimeric Antigen Receptor T Cell Pharmaceutical Circuit in One of the First Qualified European Centers. Cytotherapy 2020, 22, 792–801. https://doi.org/10.1016/j.jcyt.2020.06.009.
- 20.
Xu, J.; Chen, Z.; Su, L.; et al. In Vivo CAR Cell Therapy: From Bench to Bedside. J. Hematol. Oncol. 2025, 18, 105. https://doi.org/10.1186/s13045-025-01759-2.
- 21.
An, N.; Wang, D.; Zhang, P.; et al. In Vivo Generation of Anti-BCMA CAR-T Cells in Relapsed or Refractory Multiple Myeloma: A Phase 1 Study. Nat. Med. 2026, 32, 1257–1266. https://doi.org/10.1038/s41591-026-04244-6.
- 22.
Greco, B.; Doglio, M.; Casucci, M. Engineering in Vivo CAR-T Cells. Nat. Med. 2026, 32, 1194–1195. https://doi.org/10.1038/s41591-026-04296-8.
- 23.
Wang, R.; Yu, J.; Caligiuri, M.A.; et al. Optimizing in Vivo CAR T-Cell Engineering for Cancer Immunotherapy. Cancer Res. 2026, 86, 1823–1835. https://doi.org/10.1158/0008-5472.can-25-3748.
This work is licensed under a Creative Commons Attribution 4.0 International License.
